AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05259709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr˗DFO˗REGN5054
Description: Administered by intravenous (IV) infusion during Part A and B.
Study NCT05259709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered by IV infusion every 3 weeks (Q3W).
Study NCT05975047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIV001
Description: Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
Study NCT05975047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo across Part A and B of the study
Study NCT06673238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule
Study NCT06672133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Given：IV
Study NCT06672133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab
Description: Given：IV
Study NCT06226818 — intervention group
Intervention type: OTHER
Intervention: completion of scales and questionnaires
Description: Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances.
Study NCT05113394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM sublingual Immunotherapy
Description: HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.
Study NCT05113394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual therapy
Study NCT05629585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Experimental drug. Provided in 100mg vials. IV infusion
Study NCT05629585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Experimental drug. Provided in 50mg vials. IV infusion
Study NCT05629585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Active Comparator. Tablet. Oral route of administration
Study NCT05629585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Active Comparator. Provided in 100mg vials. IV infusion
Study NCT06384261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: CD70 monoclonal antibody
Study NCT06384261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 inhibitor
Study NCT06384261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: BCL-2 inhibitor
Study NCT06384261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Hypomethylating agent
Study NCT06384261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Hypomethylating agent
Study NCT06672133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT06671210 — intervention group
Intervention type: DEVICE
Intervention: Urine and vaginal swab self-control
Description: Each participant provided urine and vaginal swabs for HPV testing.
Study NCT05778266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: oral supplementation of pure L-citrulline (6 g) for twelve weeks
Study NCT05778266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethyl cellulose
Description: oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
Study NCT05778266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Intervals Training
Description: participants will have sessions 3 days a week for twelve weeks
Study NCT05778266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Intervals Training
Description: participants will have sessions 3 days a week for twelve weeks
Study NCT04418440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Souvenaid oral nutritional supplement (Nutricia)
Description: Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
Study NCT04982588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve™ Evolut™ PRO System
Description: The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)
Study NCT06536439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-operative explanation of the procedure (DIPLANN + CT)
Description: Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
Study NCT06536439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-operative surgical planning (DIPLANN + CT)
Description: Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.
Study NCT06536439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RAPN (DIPLANN + CT)
Description: Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.
Study NCT06536439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative explanation of the procedure (CT only)
Description: Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
Study NCT06536439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative surgical planning (CT only)
Description: Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.
Study NCT06536439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RAPN (CT only)
Description: Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of breast
Description: Undergo breast biopsy
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of breast
Description: Undergo breast biopsy
Study NCT05919108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neratinib
Description: Taken by mouth
Study NCT05919108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Taken by mouth
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammogram
Description: Undergo Mammogram
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammogram
Description: Undergo Mammogram
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo breast Magnetic Resonance Imaging
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo breast Magnetic Resonance Imaging
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Surgery
Description: Undergo Breast Surgery
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Undergo Breast Surgery
Study NCT05919108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo Ultrasound
Study NCT06003231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV, intravenous) every 2 weeks
Study NCT06563531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological thromboprophylaxis and elastic compression
Description: Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis and elastic restraint after total hip or knee arthroplasty.
Study NCT06563531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacological thromboprophylaxis without elastic compression
Description: Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis only after total hip or knee arthroplasty.
Study NCT06566482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-esketamine combination
Description: Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
Study NCT06566482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
Study NCT06023550 — intervention group
Intervention type: OTHER
Intervention: Treatment with surgery and/or conservative measures
Description: Patients will be treated according to established clinical practice with surgery and/or conservative measures.
Study NCT04656275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: BI 1323495
Study NCT04794699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion
Study NCT04656275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05601752 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells
Description: Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
Study NCT05601752 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Description: Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
Study NCT06190509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.
Study NCT06190509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant
Study NCT06190509 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine
Description: The placebo is administered twice, 2 months apart
Study NCT04383119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin in monotherapy
Study NCT04383119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, control arm
Study NCT04383119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention: Observational Cohort
Description: Treatment according clinical practice
Study NCT05440149 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No PMRT for mastectomy / No regional RT for BCS
Description: * Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
Study NCT05440149 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PMRT for mastectomy / WBI + Regional RT for BCS
Description: * Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used.
Study NCT06418425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counselling on home-based exercise program and dietary protein intake
Description: Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
Study NCT06497231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beautifil II LS
Description: Beautifil II LS is a low shrinkage bioactive giomer resin composite.
Study NCT06497231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite material
Description: Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
Study NCT05710107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PENG + LFC Block
Description: Subjects assigned to this group will receive PENG + LFC Block
Study NCT05710107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Subjects randomized to this group will receive a QL Block
Study NCT06469398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Laser System
Description: Subjects will receive up to 6 laser treatments
Study NCT06290232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Laser Photocoagulation
Description: Pregnant patients diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation of the involved fetal vessels. FLP will be performed laparoscopically using a fetoscope (tiny telescope) and a laser device inside of the womb. This procedure will be completed at 30w0d to 32w6d gestational age.
Study NCT06405074 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: low intensity focused ultrasound (LIFU)
Description: Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
Study NCT04794699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion
Study NCT04794699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Intravenous infusion
Study NCT05744869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBAT Implementation
Description: Implementation of the SBAT Program
Study NCT05744869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care for children with asthma
Study NCT05913323 — intervention group
Intervention type: DEVICE
Intervention: Rapid Expiratory Occlusion Monitor (REOM)
Description: Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
Study NCT05913323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard oscillometry
Description: tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
Study NCT05857345 — intervention group
Intervention type: OTHER
Intervention: Collection of breastmilk
Description: Collection of breastmilk and other information about the participant
Study NCT05913323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard pulmonary function test
Description: Standard-of-care respiratory test.
Study NCT06668220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
Study NCT05513521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-velocity interval training
Description: For the velocity training protocol, the 11 exercises will be completed at 40% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
Study NCT05513521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: For the load training protocol, the 11 exercises will be completed at 79% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
Study NCT06668220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.